What is Secura Bio?
Secura Bio, Inc. operates as a specialized entity dedicated to the commercialization of oncology medicines. The firm distinguishes itself through a high-touch operational model that integrates clinical research and development capabilities with strategic market access programs. By focusing on the optimization of drug pathways and the maximization of commercial outcomes, Secura Bio serves as a critical bridge between innovative oncology research and the healthcare professionals and patients who require these life-saving treatments. Their market position is defined by a commitment to transforming the potential of oncology therapies into tangible clinical results, navigating the complexities of the pharmaceutical sector with precision and expertise.
How much funding has Secura Bio raised?
Secura Bio has raised a total of $70.3M across 2 funding rounds:
Debt
$350K
Debt
$70M
Debt (2020): $350K with participation from PPP
Debt (2020): $70M led by Athyrium Capital Management
Key Investors in Secura Bio
Athyrium Capital Management
Athyrium Capital Management is a prominent investment firm specializing in structured financing for the global healthcare sector, including royalties and credit solutions.
PPP
Public-Private Partnership
What's next for Secura Bio?
With the recent influx of capital, Secura Bio is poised to scale its clinical trial infrastructure and enhance its expanded access programs. The strategic deployment of these funds will likely focus on strengthening the company's commercial pipeline and deepening its engagement with healthcare providers. As the firm continues to navigate the evolving oncology market, the focus remains on operational excellence and the successful delivery of therapeutic solutions. This phase of growth suggests a transition toward broader market penetration and the solidification of its role as a key player in the oncology commercialization space, ensuring that advanced treatments reach the patients who need them most efficiently.
See full Secura Bio company page
